Search details
1.
Ventricular septal defect complicating acute myocardial infarction: diagnosis and management. A Clinical Consensus Statement of the Association for Acute CardioVascular Care (ACVC) of the ESC, the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC and the ESC Working Group on Cardiovascular Surgery.
Eur Heart J
; 2024 Jun 18.
Article
in English
| MEDLINE | ID: mdl-38888906
2.
Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium.
Circulation
; 147(25): 1933-1944, 2023 06 20.
Article
in English
| MEDLINE | ID: mdl-37335828
3.
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk.
N Engl J Med
; 385(18): 1643-1655, 2021 10 28.
Article
in English
| MEDLINE | ID: mdl-34449185
4.
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
N Engl J Med
; 385(23): 2150-2160, 2021 12 02.
Article
in English
| MEDLINE | ID: mdl-34449183
5.
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials.
Eur Heart J
; 44(11): 954-968, 2023 03 14.
Article
in English
| MEDLINE | ID: mdl-36477292
6.
Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical Trial.
Circulation
; 145(10): 724-738, 2022 03 08.
Article
in English
| MEDLINE | ID: mdl-34747186
7.
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement.
N Engl J Med
; 382(2): 120-129, 2020 01 09.
Article
in English
| MEDLINE | ID: mdl-31733180
8.
Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis.
Eur Heart J
; 43(33): 3100-3114, 2022 09 01.
Article
in English
| MEDLINE | ID: mdl-35580836
9.
Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial.
Circulation
; 144(15): 1196-1211, 2021 10 12.
Article
in English
| MEDLINE | ID: mdl-34455849
10.
Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial.
Catheter Cardiovasc Interv
; 100(1): 72-82, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35500171
11.
Two-year clinical outcomes after successful transcatheter aortic valve implantation with balloon-expandable versus self-expanding valves: A subanalysis of the GALILEO trial.
Catheter Cardiovasc Interv
; 100(4): 636-645, 2022 10.
Article
in English
| MEDLINE | ID: mdl-36040717
12.
Predicting medical usage rate at mass gathering events in Belgium: development and validation of a nonlinear multivariable regression model.
BMC Public Health
; 22(1): 173, 2022 01 25.
Article
in English
| MEDLINE | ID: mdl-35078442
13.
Mass gathering events: a retrospective analysis of the triage categories, type of injury or medical complaint and medical usage rates.
Emerg Med J
; 39(9): 708-711, 2022 Sep.
Article
in English
| MEDLINE | ID: mdl-35393345
14.
Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial.
Circulation
; 142(5): 441-454, 2020 08 04.
Article
in English
| MEDLINE | ID: mdl-32795098
15.
External validation of the GRACE risk score 2.0 in the contemporary all-comers GLOBAL LEADERS trial.
Catheter Cardiovasc Interv
; 98(4): E513-E522, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34000088
16.
Usefulness of updated logistic clinical SYNTAX score based on MI-SYNTAX score in patients with ST-elevation myocardial infarction.
Catheter Cardiovasc Interv
; 97(7): E919-E928, 2021 06 01.
Article
in English
| MEDLINE | ID: mdl-33175478
17.
Predicting 2-year all-cause mortality after contemporary PCI: Updating the logistic clinical SYNTAX score.
Catheter Cardiovasc Interv
; 98(7): 1287-1297, 2021 12 01.
Article
in English
| MEDLINE | ID: mdl-33539048
18.
Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial.
Eur Heart J
; 41(47): 4497-4504, 2020 12 14.
Article
in English
| MEDLINE | ID: mdl-32860041
19.
One-Year Outcomes After Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: A Prespecified Analysis of the SWISS-APERO Randomized Clinical Trial.
Circulation
; 149(6): 484-486, 2024 02 06.
Article
in English
| MEDLINE | ID: mdl-37875064
20.
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
Lancet
; 394(10206): 1335-1343, 2019 Oct 12.
Article
in English
| MEDLINE | ID: mdl-31492505